Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs UBS Group AG Registered Ordinary Shares — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while UBS Group AG Registered Ordinary Shares trades at $47.31 (market cap $147.14B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 151.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and UBS Group AG Registered Ordinary Shares pays a 2.3% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and UBS Group AG Registered Ordinary Shares for 3 Days on average.
| MRVI | UBS | |
|---|---|---|
Market Cap | $972.90M | $147.14B |
Volume | 4,325,710 | 1,589,541 |
Sector | Health | Financials |
52-Week High | $9.00 | $55.72 |
52-Week Low | $2.83 | $36.41 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $1.08B | $315.77B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
UBS trades at $47.85, showing minimal daily movement with a 0.06% gain. The technical picture is bearish with mixed earnings performance - beating estimates in Q1 2026 but missing in Q4 2025 and Q2 2026. Analyst sentiment leans positive with 55% buy ratings, though the consensus price target of $23.57 sits well below current levels. Recent news highlights UBS's strategic focus on US expansion and ongoing integration challenges.
The outlook remains cautious given the bearish technical signals and valuation concerns. Investment opportunity exists in the company's improving profitability and revenue growth trajectory, but risks include integration challenges from recent acquisitions and exposure to European debt market volatility. The significant gap between current price and analyst targets warrants careful consideration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
